PTC THERAPEUTICS INITIATES STUDY OF PTC124 IN CYSTIC FIBROSIS
PTC Therapeutics has launched a Phase II study of PTC124 in patients with cystic fibrosis (CF) due to a nonsense mutation. PTC124 is a novel, orally administered drug that targets nonsense mutations and is being investigated initially as a treatment for CF and Duchenne muscular dystrophy, with the potential to treat a number of other genetic disorders.
The study is enrolling patients who have CF due to the presence of a nonsense mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The primary endpoint of the study is assessment of nasal transepithelial potential difference as a measure of CFTR function in response to treatment with PTC124. Secondary assessments of the induction of CFTR cellular protein, pulmonary function, safety, pharmacokinetics, and compliance will also be performed.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May